Pharma Won’t Fund Heroin Vaccine Trials

Pharma Won’t Fund Heroin Vaccine Trials

In the wake of the widely reported opioid addiction crisis in the United States, there has been a significant amount of speculation and discussion in the media about drug addiction vaccines, particularly for heroin. The Vaccine Reaction has been tracking this issue for several years.

Clinical Study Explores mRNA-Based Technology for Vaccines

Clinical Study Explores mRNA-Based Technology for Vaccines

On July 25, 2017, the British journal The Lancet published results of an early-stage trial that could herald the arrival of a whole new class of vaccines. CureVac, a German biopharmaceutical company that focuses on therapeutic applications using messenger RNA (mRNA), announced “proof of concept” results from their Phase I study…

The Epidemic of Silence with Adverse Drug Reactions

The Epidemic of Silence with Adverse Drug Reactions

One of the more bothersome feedback loops that keeps adverse drug reactions from being recognized is that patients stay silent about their pain and suffering, and therefore their pain and suffering is not recognized or appreciated, and everyone gets to continue to think that dangerous drugs are safe and that adverse reactions are rare.

GlaxoSmithKline Ranked Top Vaccine Maker

GlaxoSmithKline Ranked Top Vaccine Maker

GlaxoSmithKline (GSK), Merck & Co., Pfizer, and Sanofi account for 80 percent of global vaccine revenues. Although these “big four” vary significantly by portfolio and pipeline size, GSK of the United Kingdom ranked first in terms of research and development, pricing strategy and registration, and manufacturing and supply, according to a report released by the Access to…

Needle-Free Vaccines Backed by Gates Foundation

Needle-Free Vaccines Backed by Gates Foundation

The Bill & Melinda Gates Foundation recently awarded two grants worth a total of $6 million to the Boston-based life sciences company Vaxess Technologies, Inc. The grants will support research to create two micro-needle vaccine “patches” that simplify delivery of the inactivated polio (IPV) and live attenuated measles rubella (M-R) vaccines through needle-free delivery systems and […]

Hepatitis B Vaccine Global Market to Grow Over Next Decade

Hepatitis B Vaccine Global Market to Grow Over Next Decade

Hepatitis B is an infectious disease of the liver caused by the Hepatitis B virus (HBV). The symptoms of the disease do not develop until after a few weeks of exposure. Hepatitis B is usually transmitted from an infected person blood, semen and other body fluids. Hepatitis B is primarily an adult disease passed from person to person…

Pfizer, Merck, Sanofi, GSK Will Continue to Dominate the Vaccine Market

Pfizer, Merck, Sanofi, GSK Will Continue to Dominate the Vaccine Market

The monopoly that Pfizer Inc., Merck & Co. Inc., Sanofi and GlaxoSmithKline plc (GSK) have on the vaccine market is unlikely to be broken, according to Jeffrey Holford, an equity analyst at global investment banking firm Jefferies. That market is projected to grow from $28.3 billion in 2015 to $72.5 billion in 2024. The four companies…

Global Vaccine Market Surging to More Than $70 Billion by 2024

Global Vaccine Market Surging to More Than $70 Billion by 2024

Within the health care and pharmaceutical industry, the global vaccine market is one of the fastest growing segments and new predictions estimate the value of the market to reach between $48 billion and more than $70 billion over the next five to eight years. According to a new report released by Transparency Market Research, the value…

How Big Pharma Maintains Compliance, Brand Loyalty & Market Share

How Big Pharma Maintains Compliance, Brand Loyalty & Market Share

What can pharmaceutical companies do when their target audience cannot or will not comply with their prescribed medication recommendation? They target the caregiver, of course. For some patients, especially the mentally ill or the elderly, compliance is an issue. And Big Pharma does not want patients to miss a single dose of their medication. Compliance techniques are very…

World Vaccine Market Will Be Worth $77.5 Billion by 2024

World Vaccine Market Will Be Worth $77.5 Billion by 2024

A new market study by Grand View Research, Inc. of San Francisco, CA estimates the value of the world vaccine market at $32.5 billion in 2015. The study forecasts the market to grow to $77.5 billion by 2024. Grand View Research attributes the growth mainly to the “rising demand for better healthcare infrastructure and high awareness levels of the…